ESR1 and breast carcinoma: Significantly, the latter effect was observe not only in ER (+) cells, but in ER (−) breast cancer cell lines which suggest that CK2 inhibition might be a therapeutic strategy to reverse or prevent endocrine resistance on breast cancer.